Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (OtherCSBTF), CSL (OtherCMXHF) and Roche Holding AG (OtherRHHVF)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kuros Biosciences (CSBTF – Research Report), CSL (CMXHF – Research Report) and Roche Holding AG (RHHVF – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kuros Biosciences (CSBTF)
Kepler Capital analyst Christophe dombu maintained a Buy rating on Kuros Biosciences on June 16 and set a price target of CHF32.50. The company's shares closed last Wednesday at $33.22, close to its 52-week high of $36.10.
According to TipRanks.com, dombu is ranked #8486 out of 9621 analysts.
The the analyst consensus on Kuros Biosciences is currently a Hold rating.
CSL (CMXHF)
Morgan Stanley analyst David Bailey maintained a Buy rating on CSL today and set a price target of A$303.00. The company's shares closed last Tuesday at $148.56.
According to TipRanks.com, Bailey is a 4-star analyst with an average return of 16.4% and a 48.1% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Ramsay Health Care, and Cochlear.
CSL has an analyst consensus of Strong Buy, with a price target consensus of $203.87, implying a 37.2% upside from current levels. In a report released yesterday, Jarden also maintained a Buy rating on the stock with a A$317.61 price target.
Roche Holding AG (RHHVF)
Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG on June 16 and set a price target of CHF315.00. The company's shares closed last Tuesday at $321.13.
According to TipRanks.com, Evans is ranked #4919 out of 9621 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $352.85 average price target, implying an 8.3% upside from current levels. In a report issued on June 16, UBS also maintained a Buy rating on the stock with a CHF314.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Electra Battery Materials price target lowered to $2.20 from $2.40 at H.C. Wainwright
H.C. Wainwright analyst Heiko Ihle lowered the firm's price target on Electra Battery Materials (ELBM) to $2.20 from $2.40 and keeps a Buy rating on the shares following the recent announcement that a feasibility level engineering study covering the construction of a modular battery recycling facility has been completed. The firm expects this facility to recover lithium, nickel, cobalt, manganese, and graphite from lithium-ion battery manufacturing scrap and end-of-life batteries while using Electra's proprietary hydrometallurgical process, the analyst tells investors in a research note. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on ELBM: Disclaimer & DisclosureReport an Issue Electra and Three Fires Group Advance Indigenous-Led Battery Recycling in Canada Electra Battery Materials, Three Fires advance Aki Battery joint venture Electra Advances Battery Recycling with New Facility Feasibility Study Electra Battery completes feasibility study on battery recycling facility Electra Supports Ontario's $500M Critical Minerals Fund Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Walmart, Soda Health collaborate to launch Walmart Everyday Health Signals
Walmart (WMT) and Soda Health announced a collaboration to launch the Walmart Everyday Health Signals program to select Medicare Advantage and Medicaid members. This innovative initiative helps participating flex card members' wellness efforts by providing personalized nutrition and guidance based on retail shopping insights and analysis. The Walmart Everyday Health Signals program is designed to support day-to-day decisions for better health and wellbeing. By utilizing real-time retail insights and targeted benefit delivery, the program addresses key population health challenges by meeting people where they are in their everyday shopping journeys. Members who enroll in the program can opt in to receive personalized nutrition and wellness insights based on their shopping patterns on This includes key nutritional information for purchases like fruits and vegetables and identifying products to help reach wellness goals, along with customized healthy recipes and shopping lists. These data-driven insights are generated only when members opt in to participate. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on WMT: Disclaimer & DisclosureReport an Issue Amazon Gives Members 'More Time to Shop Deals' with a 4-Day Prime Day Sale #BoycottWalmart Gains Steam Post 'No Kings' Protests, Walmart Stock (NYSE:WMT) Notches Up JPMorgan says stablecoins not threat to Visa, MasterCard Morning News Wrap-Up: Friday's Biggest Stock Market Stories 'Profound AI Opportunity' for Walmart as it Takes on TikTok and Amazon Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Verve Therapeutics downgraded to Hold from Buy at Canaccord
Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash, an aggregate of approximately $1B, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on VERV: Disclaimer & DisclosureReport an Issue Verve Therapeutics downgraded to Market Perform at William Blair Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly Video: Verve, solar stocks among major pre-market movers Verve Therapeutics Merges with Eli Lilly in Acquisition Eli Lilly to acquire Verve Therapeutics for $10.50 per share in cash Sign in to access your portfolio
